WuXi Biologics retains MSCI AAA ESG rating
Analysis based on 6 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026
The sustained MSCI AAA ESG rating and index inclusion enhance ADMA Biologics' reputation among institutional investors focused on sustainability, potentially attracting ESG-focused capital. This recognition may positively influence the company's stock price and valuation in the biopharmaceutical sector.
ADMA Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on July 8, 2026, that it has achieved MSCI's highest AAA ESG rating and been included in the MSCI 2026 Selection Indexes for the fourth consecutive year. This recognition was attained under the new MSCI ESG Model 5.0, which caused rating changes for approximately 37% of rated issuers. The company's sustained performance across key ESG topics such as Product Safety and Quality, Human Capital Development, Corporate Governance, and Climate Change contributed to this achievement. Dr. Chris Chen, CEO and Chairman of the ESG Committee, highlighted that this validates the company's sustainability efforts. ADMA Biologics has also received recognition from other leading ESG rating agencies including EcoVadis, S&P Dow Jones Indices, CDP, Sustainalytics, FTSE4Good Index Series, ISS ESG, and Hang Seng Corporate Sustainability Index Series.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard